Marker Therapeutics, Inc. (MRKR)
The company now
Marker Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Houston, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $3.5 million and a loss of $12 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia | $900,014 | $4.4M | 25.4% |
| National Institutes of Health Small Business Innovation Research for Lymphoma Grant | $665,000 | $665,000 | 18.7% |
| Cprit Pancreatic Grant | $573,994 | n/a | 16.2% |
| National Institutes of Health Small Business Innovation Research | $472,208 | $982,182 | 13.3% |
| National Institutes of Health Small Business Innovation Research for Pancreatic Cancer | $425,670 | $7177.00 | 12.0% |
| National Institutes of Health National Cancer Institute Grant | $391,305 | $5822.00 | 11.0% |
| Fda Grant | $118,478 | $519,750 | 3.3% |
As tagged in its annual report (Form 10-K, filed Mar 18, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.